Lv21
125 积分 2020-08-25 加入
P3.08F.01 Interim Analysis of a Phase 2 Prospective Trial of Induction Lorlatinib in Locally Advanced ALK-Positive NSCLC (LORIN)
2小时前
求助中
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non–Small-Cell Lung Cancer
21天前
已完结
Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis
2个月前
已完结
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
3个月前
已完结
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
3个月前
已完结
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges
4个月前
已完结
Neoadjuvant and Adjuvant Treatment for Early-Stage Resectable Non-small Cell Lung Cancer (NSCLC): Consensus Recommendations from the International Association for the Study of Lung Cancer (IASLC)
4个月前
已完结
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
5个月前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
5个月前
已完结
Perioperative Nivolumab in Resectable Lung Cancer
5个月前
已完结
皖公网安备34019202002308
